You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to October 2024

AbstractFullPdf
Nov 2020444041
Dec 20207709
Jan 202140010
Feb 202147014
Mar 202168030
Apr 202190015
May 202123018
Jun 20210029
Jul 20210022
Aug 20210021
Sep 20210018
Oct 2021120029
Nov 2021104037
Dec 202198010
Jan 202290025
Feb 2022124021
Mar 202236015
Apr 2022202019
May 2022166017
Jun 2022168017
Jul 2022136014
Aug 2022166018
Sep 2022136013
Oct 2022172022
Nov 2022246026
Dec 2022148017
Jan 2023132011
Feb 2023124018
Mar 2023214029
Apr 2023198019
May 2023156019
Jun 2023176043
Jul 2023144021
Aug 2023116026
Sep 2023160036
Oct 202386010
Nov 2023149022
Dec 202312007
Jan 20244204
Feb 20248705
Mar 2024162010
Apr 2024154021
May 202494013
Jun 2024157021
Jul 2024168017
Aug 2024162016
Sep 2024173012
Oct 202421406
Total60890913